-
SinoMab BioScience’s SM17 Atopic Dermatitis Drug Reaches First Patient Milestone in Phase Ib Trial
•
SinoMab BioScience Ltd (HKG: 3681), a biotech firm based in Hong Kong, has announced the first patient dosing in a Phase Ib clinical study for SM17, a pioneering drug for atopic dermatitis (AD). The study is designed to evaluate the safety, tolerability, and pharmacokinetics of SM17, along with preliminary efficacy,…
-
SinoMab BioScience’s Suciraslimab IND Accepted for Review by China’s NMPA
•
SinoMab BioScience Ltd (HKG: 3681), a Hong Kong-based biotechnology company, has announced that the National Medical Products Administration (NMPA) in China has accepted its Investigational New Drug (IND) filing for suciraslimab for review. The company anticipates initiating a Phase I clinical study for the drug in the treatment of early…
-
SinoMab BioScience Receives NMPA Approval for Phase I Study of Atopic Dermatitis Drug SM17
•
Hong Kong-based biotechnology company SinoMab BioScience Ltd (HKG: 3681) has received approval from the National Medical Products Administration (NMPA) to conduct a Phase I clinical study in China, assessing the safety of SM17, a first-in-class drug for atopic dermatitis (AD). The study is set to commence in the fourth quarter…
